Astellas Pharma US, Inc., is a U.S. affiliate of Tokyo-based Astellas Pharma Inc., with its headquarters located in Northbrook, Illinois. More than 3,000 Astellas employees are based in the United States. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.
Our commitment to changing tomorrow is measured not only by our focus on bringing innovative and effective new medicines to patients and physicians, but also by the importance we place on the impact we can make within the communities where we work and live. Astellas supports many causes and has created Changing Tomorrow Day, an annual, worldwide volunteer event, to demonstrate this commitment.
Astellas US Headquarters
2375 Waterview Drive
Northbrook, IL 60062-6111
Phone: 800-888-7704
President, Astellas US
Mark Reisenauer
Employees Based in the US
More than 3000
U.S. Product Sales:
$4.1 Billion* (FY 2019)
*Accurate as of April 2020.
Click here for more Astellas locations
R&D Pipeline
To learn more about the progress of Astellas' clinical development projects, visit the Overview of R&D Pipeline on the Astellas Pharma Inc. website.
Major Corporate Highlights
2005 - Established U.S. headquarters near Chicago, Illinois, with the merger of Yamanouchi & Fujisawa
2008 - Established a new U.S.-based subsidiary, Astellas Pharma Global Development, Inc., which acts as the headquarters for global development
2010 - Astellas acquires New York-based OSI to support new focus on oncology
2012 - More than 1,000 employees relocate to new U.S. headquarters in Northbrook, Illinois
2016 - Astellas acquires Ocata Therapeutics, Marlboro, Mass., and establishes the Astellas Institute for Regenerative Medicine (AIRM)
2017 - Astellas opens new drug discovery and development hub in San Diego, Calif, Astellas Research Institute of America (ARIA)
2017 - Astellas acquires Mitobridge, Inc., Cambridge, Massachusetts to discover and develop compounds that target mitochondrial function
2018 - Astellas acquires Universal Cells, Inc., Seattle Washington, to develop stem cell therapies
2018 - Astellas acquires Potenza Therapeutics, Inc., Cambridge MA to build a portfolio of novel immuno-oncology therapies
2019 - Astellas acquires Xyphos Biosciences, Inc. to add talent and a proprietary therapeutic platform to accelerate next-generation cancer immunotherapy
2020 - Astellas acquires Audentes Therapeutics, Inc. to become a global leader in AAV-based genetic medicines
2020 - Astellas and Adaptimmune Therapeutics plc, Philadelphia, Penn. and Oxfordshire, UK, entered into agreement for T-cell therapies for people with cancer
2021 - Astellas integrates wholly owned subsidiary, Audentes Therapeutics, to create Astellas Gene Therapies as its Global Gene Therapy Center of Excellence
Corporate Recognition Awards
Astellas has been recognized as an employer of choice by Working Mother magazine, a best place to work for disability inclusion by the Disability Equality Index and as a best workplace for LGBTQ equality on the Human Rights Campaign’s Corporate Equality Index. To learn more, visit our Awards & Recognition section.
